# Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

> clinical trial · VERIFIED · 2026-07-22

Status: NOT_YET_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Adenocarcinoma

- Company: National Cancer Institute (NCI)
- Sector: Adenocarcinoma
- Primary source: https://clinicaltrials.gov/study/NCT07574541

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.